Brett Finlay is a microbiologist whose research explores the interaction between pathogenic bacteria, such as Salmonella and E. coli, and their host cells.
He is particularly interested in how the microbiome of humans can affect conditions such as
asthma, inflammatory bowel disease, food allergies and cardiovascular disease. Finlay is also interested in treatment and prevention of infections such as the C. difficile bacteria. In 2003, he led the successful initiative to develop a SARS vaccine.
- Officer of Canada
- Order of B.C.
- Fellow of the Royal Society of Canada
- Fellow of the Canadian Academy of Health Sciences
- CIHR Distinguished Investigator
- Sekirov, I. et al. "Gut microbiota in health and disease." Physiol. Rev. 90, no. 3 (2010): 859–904.
- Croxen, M.A., and B.B. Finlay. “Molecular mechanisms of Escherichia coli pathogenicity.” Nat. Rev. Microbiol. 8, no. 1 (2010): 26–38.
- Ivanov, I.I. et al. "Specific microbiota direct the differentiation of IL-17-producing T- helper cells in the mucosa of the small intestine." Cell Host Microbe 4, no. 4 (2008): 337–49.
- Lupp, C. et al. "Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of enterobacteriaceae." Cell Host Microbe 2, no. 2 (2007): 119–29.
CIFAR is a registered charitable organization supported by the governments of Canada, Alberta and Quebec, as well as foundations, individuals, corporations and Canadian and international partner organizations.